The continuous glucose monitor (CGM)-based offering received clearance for adults with type 2 diabetes on glargine U-100 long-acting insulin therapy. San Diego-based Dexcom says it marks the first and only CGM-integrated basal dosing optimizer cleared for type 2 diabetes.

Smart Basal uses Dexcom’s G7 15 Day sensor data and logged doses to calculate personalized daily recommendations. It guides users toward a more effective long-acting insulin dose, as directed by their healthcare provider.